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Abstract
Background: Our previous research suggested that p57 downregulation could accelerate the growth and invasion
of hepatocellular carcinoma in vitro and in vivo.
Aim: To evaluate the role of cytoplasmic p57 and its regulatory mechanism during hepatocellular carcinoma
invasion.
Methods: We examined the subcellular localization of p57 by immunohistochemistry in 45 pairs of cancerous
tissues and adjacent non-cancerous tissues. Moreover, we generated stable p57 knockdown hepatoma cell lines to
investigate the mechanism of cytoplasmic p57-mediated regulation of invasion by immunoprecipitation, confocal
immunofluorescence microscopy and western blot of nuclear and cytoplasmic extracts.
Results: Our results showed that cytoplasmic expression of p57 was reduced in specimens from patients with
capsular invasion and metastasis (P < 0.05). Moreover, the level of p-cofilin was decreased in the group lacking
cytoplasmic p57 expression (P < 0.05). Co-expression of p57 and p-cofilin was reduced in specimens from patients
with tumors at later stages (III + IV), tumors showing capsular invasion and metastatic tumors. We further observed
that p57 downregulation decreased the assembly of p57 and LIM domain kinase 1 and its kinase activity,
subsequently reducing the level of p-cofilin in the cytoplasm.
Conclusions: Cytoplasmic p57 might be a key regulator in hepatocellular carcinoma invasion via the LIM domain
kinase 1/p-cofilin pathway.
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Background
p57 is a cyclin-dependent kinase inhibitor (CKI) that be-
longs to the Cip/Kip family, which includes p21, p27 and
p57. The human p57 gene is located on chromosome
11p15.5, a region implicated in Beckwith-Wiedemann
syndrome, a familial cancer syndrome [1]. Low expression
of p57 protein has been observed in human tumors, includ-
ing carcinomas of the prostate, bladder, gastrointestinal
tract, pancreas and breast, which suggests that p57 is an
important tumor suppressor [2–4]. An increasing number
of studies have shown that p57 is a multifunctional protein
that is also involved in the regulation of transcription,
apoptosis, differentiation and motility [5, 6].
Whereas the function of Cip/Kip proteins as inhibitors
of the cell cycle is well characterized in the nucleus,
these proteins also seem to regulate cytoskeletal function
in the cytoplasm. The Cip/Kip proteins have been re-
ported to modulate the RhoA/ROCK/LIMK/cofilin sig-
naling pathways involved in tumor invasion and
metastasis. Surprisingly, p21 and p27 have been shown
to interact with Ras homolog gene family member A
(RhoA) and rho-associated, coiled-coil-containing protein
kinase 1 (ROCK1) in the cytoplasm and to accelerate can-
cer cell invasion and metastasis, suggesting a role for these
proteins that opposes the typical role of tumor suppres-
sors in the nucleus [7]. Although several studies have
reported that p57 can interact with LIM domain kinase
1 (LIMK1) to affect actin cytoskeleton dynamics, the
role of cytoplasmic p57 in the regulation of tumor cell
invasion is unclear [8].
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Hepatocellular carcinoma (HCC) is the sixth most
prevalent cancer in the world and the third leading cause
of cancer-related mortality [9]. The main reason for the
poor prognosis observed in HCC patients is the highly
proliferative and metastatic activities of HCC cells,
which are the result of the deregulation of multiple sig-
naling pathways [10]. Our previous research suggests
that the downregulation of p57 accelerates the growth
and invasion of HCC, indicating that p57 is an import-
ant tumor suppressor in HCC development [11]. More-
over, cytoplasmic expression of p57 was observed in HCC
tissue and HCC cell lines. We are thus interested in further
investigating the role and mechanism of cytoplasmic p57 in
the invasion of HCC.
Methods
Patients and samples
A total of 45 paired HCC specimens and adjacent non-
cancerous specimens were obtained from surgical resec-
tions performed at the First Affiliated Hospital, College
of Medicine, Xi’an Jiaotong University. The study partici-
pants included 36 males and 9 females with a mean age
of 48.33 ± 10.55 years (range, 29–77 years). The other
clinicopathologic data are presented in Table 1. The
pathological type of each specimen was confirmed by
independent pathologists. None of the patients re-
ceived radiotherapy or chemotherapy prior to surgery.
The TNM stage was determined using the 2002 Union
International Centre Cancer (UICC) criteria. Tumor
cellular differentiation was identified by Edmondson’s
classification. The study was approved by the Conduct of
Human Ethics Committee of the First Affiliated Hospital,
College of Medicine, Xi’an Jiaotong University. Informed
consent was obtained from each patient.
Histopathology and immunohistochemistry
Paraffin-embedded sections were deparaffinized and
rehydrated. For histopathology, the sections were stained
with hematoxylin/eosin (HE). For immunohistochemis-
try, antigens were retrieved in citrate buffer, and the sec-
tions were blocked with 3 % hydrogen peroxide and
incubated with a primary antibody against p57 (1:100, sc-
56341, Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and anti-p-cofilin (Ser3) antibody (1:100, 11139, Signalway
Antibody, Pearland, TX, USA) overnight at 4 °C. Control
sections were incubated with an isotype-matched control
antibody. Next, the sections were incubated with biotin-
conjugated secondary antibodies for 30 min and
streptavidin-peroxidase for 30 min. Immunoreactive prod-
ucts were stained with 3,3′-diaminobenzidine and subse-
quently counterstained with hematoxylin. Finally, the
sections were examined with a microscope (Q550CW;
Leica, Manheim, Germany). For the evaluation of p57 and
p-cofilin protein expression, the staining intensity was
graded and scored as follows: 0, no staining; 1, weak stain-
ing; 2, moderate staining; and 3, strong staining. The
extent of the staining was graded as 1 (≤25 %), 2 (26–
50 %), 3 (51–75 %) and 4 (≥76 %) based on the percent-
age of positively stained cells [12]. The number of posi-
tive cells was assessed by counting 10 random fields
at × 400 magnification. The final immunohistochemical
staining score was obtained by multiplying the
Table 1 Relationship between the subcellular distribution of p57 protein and clinicopathologic factors in cancerous tissues of
hepatocellular carcinoma patients





Tumor size 0.016* 0.199
<50 mm 18 4.82 ± 3.10 4.32 ± 2.92
≥50 mm 27 2.88 ± 2.65 3.18 ± 3.33
Histological grade 0.283 0.503
I + II 36 3.88 ± 3.08 3.79 ± 3.17
III 9 2.83 ± 2.48 3.08 ± 3.37
TNM stage 0.150 0.098
I + II 12 4.60 ± 3.07 4.80 ± 3.57
III + IV 33 3.30 ± 2.89 3.20 ± 2.97
Capsular invasion and extrahepatic metastasis 0.05 0.013
Positive 24 2.97 ± 2.86 2.71 ± 3.10
Negative 21 4.54 ± 2.93 4.83 ± 2.96
AFP 0.131 0.670
<400 μg · L−1 21 4.32 ± 2.84 3.84 ± 3.13
≥400 μg · L−1 24 3.10 ± 3.01 3.47 ± 3.29
n Number of patients, AFP alpha-fetoprotein, TNM tumor-node-metastasis
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intensity and the extent of staining: A score of 0–2 was
considered to be negative expression; 3–5, weak ex-
pression; 6–9, moderate expression; and 10–12, strong
expression. A score of 6–12 was defined as positive
staining, a score of 0–5 was defined as markedly re-
duced expression or a lack of expression.
Plasmids
The p57 shRNA plasmids (pGPU6/GFP/Neo-shp57) were
designed and synthesized by GenePharma Co. (Shanghai,
China). The optimal p57 shRNAs had the following
sequences: 5′-CACCGCTTTAAGAGTCATTTATATT
CAAGAGATATAAATGACTCTTAAAGCTTTTTTG-
3′ (sense) and 5′-GATCCAAAAAAGCTTTAAGAGT
CAT TTATATCTCTTGAATATAAATGACTCTTAAA
GC-3′ (antisense). The shRNA expression vector was
pGPU6/GFP/Neo (GenePharma). The plasmid pGPU6/
GFP/Neo-shNC, which encodes a hairpin siRNA with
a sequence that is not found in human genome data-
bases, was used as a negative control.
Cell culture, construction of stable transfectants and
treatments
The hepatoma cell lines HepG2, Hep3B, BEL7402,
SMMC7721, and MHCC97H and the normal liver cell
line L02 were obtained from Shanghai Cell Bank and
cultured in DMEM (Invitrogen, Carlsbad, CA, USA)
supplemented with 10 % FBS (Invitrogen), penicillin
(100 IU/ml) and streptomycin (0.1 mg/ml) at 37 °C with
5 % CO2. BEL7402 cells and SMMC7721 cells were se-
lected for our research. The cells were transfected with
shp57 and shNC plasmids using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocols.
After 24 h, the cells were diluted and selected for
1 month using G418 (Invitrogen) at 600 μg/ml for
BEL7402 cells and 800 μg/ml for SMMC7721 cells.
Stable transfectants were confirmed by western blot and
were maintained in medium containing G418 at 300 μg/ml
for BEL7402 cells and 400 μg/ml for SMMC7721 cells. The
stable p57 knockdown transfectants were named
BEL7402-shp57 and SMMC7721-shp57. HCC cells
transfected with shNC were named BEL7402-shNC
and SMMC7721-shNC, which were used as controls.
Reverse transcription PCR
Total mRNA was extracted using TRIzol reagent
(Invitrogen), and reverse transcription was performed
using an RT-PCR kit (Takara, Dalian, China). cDNA syn-
thesis was conducted with the SYBR ExScript RT-PCR kit
(Takara) according to the manufacturer’s instructions. The
PCRs consisted of 5 min at 94 °C followed by 30 cycles of
denaturation for 30 s at 94 °C, annealing for 30 s at 58 °C
and primer extension for 30 s at 72 °C. The primer se-
quences for p57 were 5′-GCGGCGATCAAGAAGCTGT-
3′ and 5′-ATCGCCCGACGACTTCTCA-3′. The primer
sequences for glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) were 5′-ACCACAGTCCATGCCATCAC-3′
and 5′-TCCACCACCCTGTTGCTGTA-3′. Each measure-
ment was performed in triplicate. GAPDH was applied as
the internal housekeeping gene control.
Western blot
Cells were lysed using cell lysis buffer as previously re-
ported [13]. Nuclear and cytoplasmic extracts were pre-
pared as previously reported [14]. Equivalent amounts of
protein were separated by SDS-PAGE (8–12 %) and trans-
ferred onto polyvinylidene fluoride membranes (Millipore,
Danvers, MA, USA). The membranes were blocked and
subsequently incubated with the following primary
antibodies: anti-p57 antibody (1:500), anti-phospho-
cofilin (Ser3) antibody (1:300, 11139, Signalway Anti-
body, Pearland, TX, USA), anti-β-actin antibody (1:1000,
sc-130301, Santa Cruz) and anti-lamin A antibody (1:600,
613501, Biolegend, San Diego, CA, USA). Blots were visual-
ized with a secondary antibody conjugated to horseradish
peroxidase (Santa Cruz) and an ECL detection system
(Millipore). Western blotting was repeated three times for
each protein.
Co-immunoprecipitation and immunoblotting
Cells were harvested and lysed in 0.1 % NP-40 lysis buffer
(50 mM Tris, pH 7.4, 250 mM NaCl, 5 mM ethylenedi-
aminetetraacetic acid, 50 mM NaF, 1 mM Na3VO4, 0.1 %
NP-40, 0.02 % NaN3, 1 mM phenylmethylsulfonyl fluoride).
For immunoprecipitation, 2 μg of anti-p57 antibody was in-
cubated with 50 μl of Dyna-beads/protein G (Invitrogen)
for 10 min at room temperature and subsequently incu-
bated with 500-μl cell lysate samples for 10 min at room
temperature with gentle rotation to form Dynabead-Ab-Ag
complexes. These complexes were then washed extensively
with phosphate-buffered saline, resolved using 10 % sodium
dodecyl sulfate–polyacrylamide gel electrophoresis and
immunoblotted with anti-LIMK1 antibody.
Confocal immunofluorescence analysis
Cells (1 × 105 per well) were fixed with 4 % paraformal-
dehyde and blocked with 5 % bovine serum and 0.3 %
Triton X-100. The cells were then incubated with anti-p57
antibody (1:100) and anti-phospho-cofilin (Ser3) antibody
(1:50) at 4 °C overnight followed by staining with TRITC-
conjugated anti-rabbit immunoglobulin (1:50, Santa Cruz)
and 1 μg/ml DAPI (Roche). Immunofluorescence was visu-
alized with a confocal laser scanning microscope (TCS SP5,
Leica, Germany).
Statistical analysis
Descriptive data were assessed using Pearson’s chi-
square test (two-sided). Quantitative data were assessed
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by Student’s t-test. P < 0.05 was considered to be statisti-
cally significant. All statistical analyses were performed
using SPSS 17.0 software for Windows (Chicago, IL).
Results
Relationship between the subcellular localization of p57
protein and clinicopathologic factors of HCC
To determine the subcellular localization of p57 protein,
immunohistochemistry was performed on 45 human
HCC tissues and adjacent non-cancerous tissues. We
noticed that p57 was expressed in both the nucleus and
cytoplasm in the HCC tissues and the adjacent non-
cancerous liver tissues (Fig. 1a, b). In the HCC tissues,
positive expression of p57 was detected in the nucleus in
14 samples and in the cytoplasm in 17 samples (Add-
itional file 1: Figure S1). To determine the association
between subcellular localization and p57 function, we
further analyzed the relationship of the nuclear and
cytoplasmic p57 with clinicopathological factors. The re-
sults showed that nuclear expression of p57 was reduced in
specimens from patients with smaller tumors (P < 0.05) and
that cytoplasmic expression of p57 was reduced in speci-
mens from patients with capsular invasion and metastasis
(P < 0.05) (Table 1). These data indicated that the cytoplas-
mic localization of p57 may have a biological function re-
lated to HCC invasion.
Association of cytoplasmic expression of p57 with p-cofilin
in HCC tissues
It is well known that LIMK1 phosphorylates cofilin at
Ser-3 and blocks the ability of cofilin to depolymerize
actin filaments during cell migration [15]. Our previous
data suggested that p57 downregulation accelerated the
invasion of HCC cells by controlling the activity of
LIMK1 and subsequently reducing the phosphorylation
of cofilin [11]. To further elucidate whether p57 regulates
HCC cell invasion in the cytoplasm, immunohistochemistry
of p-cofilin was performed in human HCC tissues. The re-
sults indicated that p-cofilin was localized only in the
cytoplasm (Fig. 1c). Moreover, we observed that of the
samples with increased cytoplasmic p57 expression, 14
samples were positive for p-cofilin expression, and of the
samples with decreased cytoplasmic p57 expression, 15
samples were negative for p-cofilin expression (P < 0.05).
We further analyzed the association of cytoplasmic co-
expression of p57 and p-cofilin with clinicopathological fac-
tors. The results showed that cytoplasmic co-
expression of p57 and p-cofilin was reduced in speci-
mens from patients with tumors at later stages (III +
IV) and patients with capsular invasion and metastasis
(P < 0.05) (Table 2). These data suggest that p57 and p-
cofilin might function in the cytoplasm to regulate
HCC invasion.
p57 regulates the level of p-cofilin in the cytoplasm of
HCC cells
We next investigated the role of p-cofilin protein in
p57-knockdown hepatoma cell lines. We selected the
BEL7402 and SMMC7721 cell lines for the follow-up
experiments because they exhibit moderate p57 ex-
pression, in contrast with the normal liver cell line
LO2 (Fig 2a). Out of four p57 shRNAs, we selected p57-
shRNA4 because it induced optimal downregulation of p57
mRNA and protein (Fig 2b, c). Stable transfectants with
downregulated p57 expression were constructed, and we
observed that the level of p57 mRNA and protein was de-
creased in BEL7402-shp57 and SMMC7721-shp57 com-
pared to BEL7402-shNC and SMMC7721-shNC (Fig 2d, e).
Our previous experiments showed that p57 did not affect
the level of LIMK1 but could affect the level of p-cofilin,
which is the unique substrate of LIMK1 and reflects its ac-
tivity [11]. However, the mRNA level of cofilin has no
change in BEL7402-shp57 and SMMC7721-shp57 com-
pared to BEL7402-shNC and SMMC7721-shNC cells
(Additional file 2: Figure S2). We questioned whether p57
could directly bind LIMK1 to affect its activity. By co-
immunoprecipitation, we further proved that p57 downreg-
ulation inhibited the assembly of p57 and LIMK1, indicat-
ing that p57 could combine with LIMK1 and regulate its
kinase activity (Fig. 2f).
Fig. 1 Immunohistochemical staining of p57 and p-cofilin protein in cancerous tissues and adjacent non-cancerous tissues of hepatocellular carcinoma
patients (×200). a Positive expression of p57 in both the nucleus and the cytoplasm of adjacent non-cancerous tissues. b In contrast with adjacent
non-cancerous tissues, positive p57 expression in the cytoplasm is decreased in the specimen with extrahepatic metastasis. c Positive p-cofilin expression
in the cytoplasm is decreased compared to adjacent non-cancerous tissues in the specimen with extrahepatic metastasis. Each inset shows images taken
at × 400 magnification
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To further verify whether p57 regulates the activity of
LIMK1 in the cytoplasm, confocal immunofluorescence
microscopy and western blot analysis of nuclear and
cytoplasmic extracts were performed. In BEL7402-shNC
and SMMC7721-shNC cells, we observed that p57 was
expressed in both the nucleus and the cytoplasm, whereas
p-cofilin was only expressed in the cytoplasm. p57 down-
regulation decreased the level of p-cofilin in the cytoplasm
in BEL7402-shp57 and SMMC7721-shp57 cells (Fig. 3a, b).
These findings demonstrated that p57 might affect the level
of p-cofilin by regulating the kinase activity of LIMK1 in
the cytoplasm.
Discussion
Increasing evidence has indicated that the Cip/Kip
family of proteins has a role in cell migration and
tumor metastasis [7]. Some clinical studies have shown
that decreased expression of p57 is related to increased
invasion and metastasis in cancers, categorizing this
protein as a suppressor of tumor metastasis [16, 17].
Inducible expression of p57 in glioma cell lines defi-
cient in this CKI reduces their motility and invasion
[18]. In addition, p57 is involved in angiogenesis,
which is an important event in cancer metastasis, via
the regulation of vascular endothelial growth factor
(VEGF) mRNA and protein levels [19]. p21 and p27,
which are other Cip/Kip family members, were shown
to regulate cell motility and invasion in the cytoplasm.
However, the role of cytoplasmic p57 and its relation-
ship with biological functions are unclear. Our study
Table 2 Association of cytoplasmic co-expression of p57 and
p-cofilin with clinicopathologic factors in cancerous tissues of
hepatocellular carcinoma patients





<50 mm 18 7 11
≥50 mm 27 7 20
Histological grade 0.428
I + II 36 10 26
III 9 4 5
TNM stage 0.004
I + II 12 8 4
III + IV 33 6 27
Capsular invasion and extrahepatic metastasis 0.009
Positive 24 3 21
Negative 21 11 10
AFP 0.520
<400 μg · L−1 21 8 13
≥400 μg · L−1 24 6 18
n Number of patients, AFP alpha-fetoprotein, TNM tumor-node-metastasis
Fig. 2 p57 knockdown in hepatoma cell lines and p57 interaction with LIM domain kinase 1. a Western blot analysis of p57 expression in hepatoma cell
lines and a normal liver cell line. b Reverse transcription polymerase chain reaction amplification of p57 mRNA in BEL7402 cells transfected with four p57
shRNAs. c Western blot analysis of p57 expression in BEL7402 cells transfected with four p57 shRNAs. d Reverse transcription polymerase chain reaction
amplification of p57 mRNA in BEL7402-shNC, BEL7402-shp57, SMMC7721-shNC and SMMC7721-shp57 cells. eWestern blot detection of p57 protein in
BEL7402-shNC, BEL7402-shp57, SMMC7721-shNC and SMMC7721-shp57 cells. f Co-immunoprecipitation was used for the detection of the association
between p57 and LIM domain kinase 1 in hepatoma cell lysates following different treatments. β-actin was used as an internal control. Glyceraldehyde
3-phosphate dehydrogenase was applied as the internal housekeeping gene control. The expression of each protein was detected by western blot in at
least three separate experiments, and representative images are shown. LIMK1, LIM domain kinase 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase;
IP, co-immunoprecipitation; WB, western blot
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showed that p57 was localized to both the nucleus and
the cytoplasm of normal liver cells and HCC cells. A
correlation analysis indicated that nuclear p57 was reduced
in specimens from patients with smaller tumors, and cyto-
plasmic p57 was reduced in specimens from patients with
capsular invasion and metastasis. These results suggest that
nuclear localization of p57 might regulate cellular prolifera-
tion and that cytoplasmic localization of p57 might regulate
cell motility. However, the mechanism of action of p57 is
different from that of p21 and p27. Cytoplasmic p21 was
found to inhibit the activity of ROCK1, reduce the forma-
tion of actin stress fibers, and promote the invasion and
metastasis of tumor cells [20]. In HCC, melanoma and
breast cancer cells, cytoplasmic expression of p27 was
found to promote migration and metastasis by inhibit-
ing RhoA activity [21]. These findings indicate that
cytoplasmic p21 and p27 might play a role as onco-
genes in some human cancers. However, our results
showed that cytoplasmic p57 inhibits the invasion and
metastasis of HCC.
Cofilins are actin-binding proteins that play an es-
sential role in regulating actin filament dynamics and
reorganization by stimulating the severing and
depolymerization of actin filaments in cell motility
and cancer metastasis [22]. It is well known that cofi-
lin is inactivated by phosphorylation by LIMK1, and
the level of p-cofilin can reflect the activity of LIMK1.
The interaction between p57 and LIMK1/p-cofilin has
been reported in human cells [23, 24]. In HCC tissues,
we found that cytoplasmic p57 was positively corre-
lated with cytoplasmic p-cofilin. More importantly, co-
expression of p57 and p-cofilin was reduced in specimens
from patients with tumors at later stages (III + IV) and
patients with capsular invasion and metastasis. Moreover,
we found that p57 downregulation decreased the assembly
of p57 and LIMK1. The results of confocal immunofluores-
cence microscopy and western blot analysis of nuclear and
cytoplasmic extracts further supported the hypothesis that
p57 could regulate the level of p-cofilin in the cytoplasm.
These data suggested that p57 might regulate the kinase
Fig. 3 p57 regulates the expression of p-cofilin in the cytoplasm. a Confocal immunofluorescence microscopy analysis of BEL7402-shNC, BEL7402-shp57,
SMMC7721-shNC and SMMC7721-shp57 cells. Green fluorescence represents the transfected plasmid, red fluorescence shows the expression of the target
protein, and blue fluorescence shows the nucleus. b Western blot analysis of nuclear and cytoplasmic extracts of p-cofilin in BEL7402-shNC, BEL7402-shp57,
SMMC7721-shNC and SMMC7721-shp57 cells. β-actin was used as an internal control for cytoplasmic proteins. Lamin A was used as an internal control for
nuclear proteins. GFP, Green fluorescent protein; TRITC, tetramethylrhodamine; DAPI, 4′,6-diamidino-2-phenylindole
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activity of LIMK1 and subsequently reduce the level of
p-cofilin in the cytoplasm to regulate HCC invasion.
Thus far, the mechanism regulating the subcellular
localization of p57 has remained undefined, although it
has been reported that phosphorylation and ubiquitina-
tion are two main mechanisms involved in this process.
In breast cancer, Akt was found to interact with p57 and
cause cytoplasmic localization of p57 by phosphorylating
its Ser282 or Thr310 residue. Akt activity resulted in
destabilization of p57 by accelerating the turnover rate
of p57 and enhancing p57 ubiquitination. Importantly,
the negative impact of HER2/Akt on p57 stability con-
tributed to HER2-mediated cell proliferation, transform-
ational activity and tumorigenicity [25]. These findings
suggested that the AKT pathway might regulate p57
subcellular localization and subsequently affect its
biological function. Importantly, phosphorylation is often
coordinated with ubiquitination in the process of p57 deg-
radation. In osteoblast cells, FBL12 was found to form an
SCF (FBL12) complex and directly ubiquitinate p57, caus-
ing p57 degradation in a phosphorylation-dependent man-
ner [26]. Another E3 ligase, Skp2, could also mediate the
ubiquitination of p57 by collaborating with CSN6 in the
cytoplasm to regulate tumor progression [27]. These stud-
ies indicated that p57 might be exported from the nucleus
due to phosphorylation and degraded in the cytoplasm
due to ubiquitination during tumor growth and invasion.
Conclusions
Our data indicated that reduced cytoplasmic p57 expres-
sion is associated with HCC invasion. Furthermore, p57
inhibits HCC invasion by regulating the level of p-cofilin
in the cytoplasm via interaction with LIMK1, suggesting
that cytoplasmic p57 may be a key regulator of HCC in-
vasion. However, some questions remain concerning the
mechanisms by which the subcellular localization of p57
regulates HCC progression. In the future, we will further
investigate the mechanism of nuclear-cytoplasmic shut-
tling of p57. Additionally, we will explore components of
this mechanism as promising targets for HCC preven-
tion and therapy.
Additional files
Additional file 1: Figure S1. Immunohistochemical staining of nuclear
p57 protein in adjacent non-cancerous tissues (left) and cancerous tissues
(right) of hepatocellular carcinoma patients (×200).
Additional file 2: Figure S2. p57 downregulation can not affects the
mRNA level of p-cofilin in HCC cell lines. Reverse transcription PCR
analysis of BEL7402-shNC, BEL7402-shp57, SMMC7721-shNC and
SMMC7721-shp57 cells.
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